Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MITF | O75030 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958431 | 1.00 | LMNA (0.68) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL461911 | 0.86 | ALDH1A1 (0.64) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL29965768 | 0.83 | POLB (0.72) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL28185573 | 0.83 | ALDH1A1 (0.60) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL29848366 | 0.83 | NR4A2 (0.67) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL535878 | 0.83 | POLB (0.72) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL1887873 | 0.83 | NR4A2 (0.67) | LMNAALDH1A1KMT2AMITFMAPT | |
| Hydrochloric Acid SCHEMBL2434452 | 0.81 | POLB (0.70) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL2174829 | 0.81 | NR4A2 (0.65) | LMNAALDH1A1KMT2AMITFMAPT | |
| SCHEMBL4658573 | 0.81 | NR4A2 (0.73) | LMNAALDH1A1KMT2AMITFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| WO-2024159211-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-112442010-B | Prodrug compounds and application thereof in treating cancers | 润佳（苏州）医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11634400-B2 | Micheliolide derivatives, methods for their preparation and their use as anticancer and antiinflammatory agents | UNIVERSITY OF ROCHESTER (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| CN-112442010-A | Prodrug compound and application thereof in treating cancer | 润佳（苏州）医药科技有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-5849918-A | Amino acid derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds | BOEHRINGER INGELHEIM KG (DE) | 1998-12-15 | — | — | US | disclosed |
| US-5596000-A | NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 1997-01-21 | — | — | US | disclosed |
| US-5446050-A | Azabicyclo amides and esters as 5-HT3 receptor antagonists | PFIZER INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0434202-B1 | Azabicyclo amides and esters as 5-HT3 receptor antagonists | PFIZER (US) | 1994-06-08 | — | — | EP | disclosed |
| CN-1086222-A | Amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM KG (DE) | 1994-05-04 | — | — | CN | disclosed |
| EP-0434202-A1 | Azabicyclo amides and esters as 5-HT3 receptor antagonists | PFIZER INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| US-5026722-A | Antagonists of 5-hydroxytryptamine | GLAXO GROUP LIMITED (GB) | 1991-06-25 | — | — | US | disclosed |
| EP-0347229-A1 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
| US-3980668-A | Anti-arrhythimic 5-endo-(3-indolecarbonyloxy)-N-[amino-(lower)alkyl]bicyclo[2,2,1]heptane-2,3-di-endo-carboxylic acid imides | BRISTOL-MYERS COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
| US-3980667-A | Anti-arrhythmic 5-endo-substituted oxy-N-(aminoloweralkyl)bicycle [2.2.2.]oc | BRISTOL-MYERS COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | LMNA 1902/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | LMNA 2478/4885ALDH1A1 3045/4885KMT2A 2558/4885 |
| US-11634400-B2 | Micheliolide derivatives, methods for their preparation and their use as anticancer and antiinflammatory agents | TNF, C9, CYP51A1 | LMNA 955/4885ALDH1A1 1456/4885KMT2A 1250/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | LMNA 1902/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | LMNA 1902/4885ALDH1A1 3019/4885KMT2A 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.